Introduction
============

The increasing prevalence of non-alcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), has recently become a major health concern worldwide ([@B1]). NAFLD/NASH is closely related to metabolic disorders such as hyperinsulinemia, diabetes, dyslipidemia, visceral adiposity, and hypertension, which are considered the hepatic phenotype of metabolic syndrome, with increased risks of morbidity and mortality related to cardiovascular diseases ([@B2]-[@B4]).

Chronic liver diseases are sometimes complicated with other liver diseases, such as hepatitis C overlapping NAFLD/NASH, which involves a more aggressive inflammatory condition and progressive stage ([@B5]). In addition, NAFLD/NASH can overlap autoimmune hepatitis (AIH) ([@B6]), and this has a reported worldwide prevalence of 1.8-3.6% ([@B7]) and a prevalence of 1.9% in Japan ([@B8]).

Anti-nuclear antibodies (ANAs), an essential diagnostic criterion for AIH, are positive in 20-33% of patients with NAFLD/NASH ([@B7],[@B9]). Consequently, ANA-positive women with NASH are sometimes misdiagnosed with AIH. Therefore, histological confirmation with a liver biopsy is critical for a definitive diagnosis of NASH overlapping AIH ([@B10],[@B11]). There are few reports on the role of a liver biopsy in developing a treatment strategy for NASH overlapping AIH. We herein report a case in which the histological confirmation of AIH led to remission with appropriate corticosteroid therapy in a deteriorating patient with NASH overlapping AIH.

Case Report
===========

A 64-year-old woman (height: 156 cm, body weight: 61.0 kg, body mass index: 25.1 kg/m^2^), who had been taking oral drugs to treat type 2 diabetes and hypertension, was diagnosed with liver injury based on blood tests. She had no other remarkable medical history, and there was no evidence of endocrine disease. She had no history of any digestive or gynecological surgeries. There was also no drinking history. Abdominal ultrasonography and computed tomography (CT) revealed fatty changes and the appearance of chronic liver disease with splenomegaly, but no ascites ([Fig. 1](#g001){ref-type="fig"}). Various viral hepatitis markers, ANA, and anti-mitochondrial antibody were negative, and the serum immunoglobulin fraction was normal ([Table 1](#t001){ref-type="table"}). The liver biopsy showed mild interface hepatitis in the mild inflamed portal tracts in addition to steatohepatitis, including moderate steatosis (20%), some focal necrosis ([Fig. 2a](#g002){ref-type="fig"}), perivenular/pericellular fibrosis ([Fig. 2b](#g002){ref-type="fig"}), ballooning hepatocytes ([Fig. 2c](#g002){ref-type="fig"}), and Mallory-Denk bodies ([Fig. 2d](#g002){ref-type="fig"}). She was classified as Matteoni classification type 4 and Brunt classification grade 1 stage 4. Her NAFLD activity score (NAS) was 4 (steatosis 1; lobular inflammation 1; and hepatocyte ballooning 2). Her international AIH score increased to 18 points.

![Abdominal CT showing liver deformity and splenomegaly, indicating advanced chronic liver disease. No hepatocellular carcinoma or ascites was evident.](1349-7235-57-0807-g001){#g001}

###### 

Laboratory Data at the First Time of Liver Biopsy.

  -------- ------------ -------- -------- ------ ------- ------------ ------- -------
  WBC      6.9×10^3^    /mm^3^   T-Bil    0.5    mg/dL   IgG          1,608   mg/dL
  Neu      55           \%       D-Bil    0.3    mg/dL   IgA          479     mg/dL
  Eos      6.0          \%       ALP      428    IU/L    IgM          182     mg/dL
  Baso     0            \%       γ-GTP    68     IU/L    HA           92.4    ng/mL
  Lym      34           \%       AST      43     IU/L    AFP          4.3     ng/mL
  Mono     5.0          \%       ALT      32     IU/L    ANA                  ×40
  RBC      4.1×10^6^    /mm^3^   LDH      227    IU/L    Anti-M2 Ab           (-)
  Hb       12.1         g/dL     ZTT      12.1   U       HBs-Ag               (-)
  Ht       37.1         \%       TTT      7.3    U       HBs-Ab               (-)
  Plt      12.4×10^4^   /mm^3^   TP       7.9    g/dL    HCV-Ab               (-)
  PT-INR   1.13                  Alb      4.2    g/dL    FBS          135     mg/dL
  BUN      17.5         mg/dL    T-chol   191    mg/dL   HbA1c        6.0     \%
  Cre      0.63         mg/dL    HDL-C    50     mg/dL                        
                                 LDL-C    112    mg/dL                        
                                 TG       145    mg/dL                        
                                 UA       4.8    mg/dL                        
  -------- ------------ -------- -------- ------ ------- ------------ ------- -------

HA: hyaluronic acid, Ab: anti-body, ANA: anti-nuclear antibody, FBS: fasting blood sugar, TG: triglyceride, UA: Uric acid

![Liver pathology at the time of the initial diagnosis (a). Hematoxylin and Eosin (H&E) staining shows mild interface hepatitis in the portal area. Focal necrosis of hepatocytes and steatosis are observed (b). Azan staining shows perivenular and pericellular fibrosis forming bridging (c). H&E staining shows ballooning hepatocytes and Mallory-Denk bodies (d).](1349-7235-57-0807-g002){#g002}

Consequently, the patient was diagnosed with advanced chronic liver disease caused by mainly NASH. Her treatment involved improved control of her diabetes and lifestyle follow-up.

After about 4 years on this therapy, her liver function test results again worsened with an IgG of 2,871 mg/dL and a serum ANA titer of over 2,560 times the normal amount ([Table 2](#t002){ref-type="table"}). We repeated the liver biopsy, which revealed steatosis with moderate perivenular/pericellular fibrosis forming bridging ([Fig. 3a, b](#g003){ref-type="fig"}), mild interface hepatitis ([Fig. 3c](#g003){ref-type="fig"}) in the moderately inflamed portal tracts with several plasma cells ([Fig. 3d](#g003){ref-type="fig"}), and hepatic rosettes ([Fig. 3e](#g003){ref-type="fig"}) \[Matteoni classification type 4; Brunt classification grade 2, stage 4; and NAS score of 4 (steatosis 1; lobular inflammation 1; and hepatocyte ballooning 2)\]. Her international AIH score increased to 20 points. Since she was diagnosed with NASH overlapping AIH, oral corticosteroid therapy was initiated at 30 mg of prednisolone daily.

###### 

Laboratory Data at the Second Time of Liver Biopsy.

  -------- ----------- -------- ---------- ------ ------- ------------ ------------------ ----------
  WBC      4.0×10^3^   /mm^3^   T-Bil      1.0    mg/dL   IgG          2,871              mg/dL
  Neu      59.1        \%       D-Bil      0.5    mg/dL   IgA          524                mg/dL
  Eos      3.5         \%       ALP        302    IU/L    IgM          135                mg/dL
  Baso     0.5         \%       γ-GTP      99     IU/L    HA           735                ng/mL
  Lym      28.8        \%       AST        114    IU/L    AFP          6.8                ng/mL
  Mono     8.1         \%       ALT        58     IU/L    ANA                             ×\>2,560
  RBC      4.0×10^6^   /mm^3^   LDH        270    IU/L                 speckled pattern   
  Hb       12.2        g/dL     ZTT        16.0   U       Anti-M2 Ab                      (-)
  Ht       35.3        \%       TTT        23.0   U       HBs-Ag                          (-)
  Plt      8.5×10^4^   /mm^3^   TP         7.8    g/dL    HBs-Ab                          (-)
  PT-INR   1.17                 Alb        3.9    g/dL    HCV-Ab                          (-)
  BUN      16.1        mg/dL    T-Chol     125    mg/dL   FBS          111                mg/dL
  Cre      0.64        mg/dL    HDL-C      50     mg/dL   HbA1c        5.9                \%
                                LDL-C      32     mg/dL                                   
                                TG         114    mg/dL                                   
                                UA         6.4    mg/dL                                   
                                Ferritin   86.8   ng/dL                                   
  -------- ----------- -------- ---------- ------ ------- ------------ ------------------ ----------

HA: hyaluronic acid, Ab: anti-body, ANA: anti-nuclear antibody, FBS: fasting blood sugar, TG: triglyceride, UA: Uric acid

![Liver pathology showing worsening of AIH-like disease activity. Hematoxylin and Eosin (H&E) staining shows steatohepatitis with moderate focal necrosis of hepatocytes (a). Azan staining shows moderate perivenular and pericellular fibrosis forming bridging (b). H&E staining shows moderate portal inflammation with mild interface hepatitis (c) and several plasma cells (d). The arrow indicates hepatic rosettes (e). AIH: autoimmune hepatitis](1349-7235-57-0807-g003){#g003}

Although the IgG level and ANA titer decreased, the liver function test results did not improve. Furthermore, we observed increases in her body weight and HbA1c level. We postulated that the NASH disease activity had worsened, while the AIH had improved. This was confirmed histologically with a liver biopsy after six months of corticosteroid therapy. The histology results showed an improvement in interface hepatitis and portal inflammation with several plasma cells, but steatosis was still observed ([Fig. 4](#g004){ref-type="fig"}) \[Matteoni classification type 4; Brunt classification grade 2, stage 4; and NAS score of 5 (steatosis 1; lobular inflammation 2; and hepatocyte ballooning 2)\]. The CT results did not show a change in the extent of her fatty liver, although her liver fibrosis had progressed ([Fig. 5](#g005){ref-type="fig"}). Her international AIH score decreased to 15 points. Therefore, we focused on improving the control of her diabetes with insulin therapy (Insulin lispro 16 Units, 16 Units, 16 Units) and lifestyle changes. These treatments led to not only an improvement in her diabetes and body weight but also an improvement in her liver function test results ([Fig. 6](#g006){ref-type="fig"}).

![Liver histology after steroid therapy. Hematoxylin and Eosin (H&E) staining shows an improvement in portal inflammation and interface hepatitis and the absence of plasma cell infiltration and hepatic rosettes (a, b). H&E staining shows that steatosis with ballooning hepatocytes is still present (c).](1349-7235-57-0807-g004){#g004}

![Abdominal plain CT shows no changes in the extent of fatty liver, although her liver fibrosis progressed.](1349-7235-57-0807-g005){#g005}

![Summary of the clinical course.](1349-7235-57-0807-g006){#g006}

Discussion
==========

We reported a patient with NASH overlapping AIH with corticosteroid therapy, which led to improved focal necrosis and interface hepatitis confirmed histologically with an improvement in the serum IgG level and ANA titer, but the development of steatosis as the NASH worsened.

Although NASH occasionally overlaps AIH, it is difficult to diagnose the presence of overlapping AIH because the serum ANA titer is sometimes positive in NASH patients. It is very important to diagnose AIH because steroid therapy, which is the first-line therapy for AIH, often exacerbates NASH due to worsening of fatty liver and diabetes, as in our case. Although no criteria have been established for diagnosing NASH overlapping AIH, coexisting AIH has distinct histological features, such as interface hepatitis and rosette formation, in addition to the histological features of NASH ([@B12]). Our patient had more marked interface hepatitis in the portal area than is typical in NASH patients, with elevated serum IgG levels and ANA titer. The serum IgG concentration has been recognized as an essential marker for diagnosing and treating AIH. The improvement in the serum IgG concentration, interface hepatitis, and portal inflammation confirmed the presence of NASH overlapping AIH in our case. However, we can minimize the steroid-induced worsening of NASH by controlling patients' body weight and metabolic abnormalities, such as diabetes, that often coexist with NASH ([@B13]). If the NASH is not under control because of steroid therapy, azathioprine or ursodeoxycholic acid is recommended to control NASH overlapping AIH ([@B8]).

The liver is a central immune organ with high exposure to circulating antigens and endotoxins via the gut microbiota. It contains many innate immune cells, such as macrophages and innate lymphoid cells ([@B14]), and Toll-like receptor signaling or inflammasome activation initiates inflammatory responses in the liver. Innate immune activation plays a crucial role in triggering and the progression of hepatic inflammation, injury, and fibrosis in NASH ([@B15],[@B16]), as in AIH ([@B17]). Therefore, further studies are needed to clarify the common points and differences in the host immune response in NASH overlapping AIH in order to establish a treatment strategy and elucidate the disease state.

In conclusion, histological confirmation is useful for determining the disease status and selecting a therapeutic strategy in patients with NASH overlapping with AIH. Steroid therapy is necessary to treat the condition when the presence of focal necrosis is confirmed through a liver biopsy. However, we must be careful, as steroid therapy can worsen NASH.
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